Replicor 更新了理解 HBV 功能性治愈方法的概念

StephenW

Replicor 更新了理解 HBV 功能性治愈方法的概念

蒙特利尔，2022 年 5 月 2 日——Replicor Inc. 宣布其 CSO Andrew Vaillant 博士参加了 2022 年 4 月 25 日至 27 日在美国马萨诸塞州波士顿举行的第二届 CHB 药物开发大会（点击此处）。

Vaillant 博士就以下重要主题介绍了该领域的最新情况：

1. 了解正在开发的药物针对 HBV 亚病毒颗粒 (HBsAg) 的相对影响和作用机制，请单击此处。https://replicorinc.cmail19.com/t/d-l-fjylkjd-kijickk-y/

2. 关于当前开发中针对 cccDNA 的药剂的影响以及实现灭菌治愈方面的挑战的经验教训，请单击此处。https://replicorinc.cmail19.com/t/d-l-fjylkjd-kijickk-j/

3. 在治疗期间清除亚病毒颗粒和转氨酶耀斑的发展对于实现功能性治愈至关重要，请单击此处。https://replicorinc.cmail19.com/t/d-l-fjylkjd-kijickk-h/

Vaillant 博士评论说：“我们对开发中的不同药物如何在临床试验中发挥作用的不断理解将继续为该领域提供各种联合疗法实现 HBV 功能性治愈的潜力”。

关于 Replicor

Replicor 是一家私营生物制药公司，在开发 HBV 和 HDV 治疗方法方面拥有最先进的动物和人类临床数据。公司致力于加速开发针对 HBV 和 HBV/HDV 合并感染患者的有效治疗方法。有关 Replicor 的更多信息，请访问我们的网站 www.replicor.com。

StephenW

Replicor updates concepts in understanding approaches to functional cure of HBV

MONTREAL, May 2nd, 2022 – Replicor Inc., announced the participation of its CSO, Dr. Andrew Vaillant, at the 2nd Annual CHB Drug Development Congress, held April 25 – 27th, 2022 in Boston, MA, USA (click here).

Dr. Vaillant presented updates in the field on the following important topics:

1.      Understanding of the relative impact and mechanisms of action of agents in development to target HBV subviral particles (HBsAg) click here.https://replicorinc.cmail19.com/t/d-l-fjylkjd-kijickk-y/

2.      Lessons learned regarding the impact of current agents in development to target cccDNA and challenges in achieving sterilizing cure click here.https://replicorinc.cmail19.com/t/d-l-fjylkjd-kijickk-j/

3.      The critical importance of both clearing subviral particles and the development of transaminase flares during therapy in achieving functional cure click here.https://replicorinc.cmail19.com/t/d-l-fjylkjd-kijickk-h/

Dr. Vaillant commented, “our evolving understanding of how different agents in development are working in clinical trials will continue to inform the field on the potential of various combination therapies to achieve functional cure of HBV”.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

齐欢畅

newchinabok

我有七，八年没看论坛的贴子内容了，看不看好像都一样，乙肝治愈不知猴年马月